EASL 2012: Brivanib Did Not Improve Overall Liver Cancer Survival, but Did Show Anti-tumor Activity
- Details
- Category: Liver Cancer/HCC
- Published on Friday, 27 April 2012 00:00
- Written by Liz Highleyman
The experimental cancer drug brivanib did not lengthen overall survival for patients with hepatocellular carcinoma, but it did increase time to progression, demonstrating that it had anti-tumor activity, researchers reported at the 47th International Liver Congress (EASL 2012) last week in Barcelona.
Complete Coverage of the 2012 International Liver Congress
- Details
- Category: HBV Treatment
- Published on Wednesday, 25 April 2012 00:00
- Written by Liz Highleyman
HIVandHepatitis.com coverage of the 2012 International Liver Congress -- 47th Annual Meeting of the European Association for the Study of the Liver (EASL), April 18-22.
Conference highlights include experimental hepatitis C therapies, interferon-free regimens, boceprevir (Victrelis) and telaprevir (Incivek/Incivo) in real-world practice, difficult-to-treat patients, HIV/HCV coinfection, hepatitis B research, and liver cancer research.
HIVandHepatitis.com EASL 2012 conference section
4/25/12
EASL 2012: Boceprevir Improves Cure Rates for HIV/HCV Coinfection but Beware of Drug Interactions
- Details
- Category: EASL 2012
- Published on Tuesday, 24 April 2012 00:00
- Written by Liz Highleyman
Adding boceprevir (Victrelis) to pegylated interferon and ribavirin for treatment of chronic hepatitis C in people with HIV substantially increased the likelihood of end-of-treatment response and sustained response 12 weeks after completing therapy, researchers reported at the 47th International Liver Congress (EASL 2012) last week in Barcelona.
EASL 2012: Entecavir (Baraclude) Prevents Hepatitis B Recurrence after Liver Transplant
- Details
- Category: HBV Treatment
- Published on Tuesday, 24 April 2012 00:00
- Written by Liz Highleyman
No patients treated with entecavir (Baraclude) after receiving liver transplants due to complications of chronic hepatitis B experienced virological recurrence, according to a study described at the 47th International Liver Congress (EASL 2012) last week in Barcelona.
EASL 2012: Alisporivir + Ribavirin Is Effective for Hepatitis C, but Pancreatitis Remains a Concern
- Details
- Category: HCV Treatment
- Published on Monday, 23 April 2012 00:00
- Written by Liz Highleyman
Alisporivir (formerly Debio 025) in interferon-free combinations cured more than 80% of patients with hepatitis C virus (HCV) genotype 2 or 3, researchers reported the 47th International Liver Congress (EASL 2012) last week in Barcelona. The drug has been put on hold, however, due to a small number of recipients developing life-threatening pancreas inflammation.
More Articles...
- EASL 2012: Simeprevir (TMC435) Improves Response Rates for Difficult-to-Treat Hepatitis C Patients
- EASL 2012: Telaprevir and Boceprevir Effective but Cause Serious Side Effects in Patients With Cirrhosis
- EASL 2012: Entecavir plus Tenofovir for Hepatitis B Patients with Prior Treatment Failure
- EASL 2012: GS-7977, Daclatasvir, and Asunaprevir Look Good in Interferon-Free Regimens for Hepatitis C
Web Design and Development by